Key result
Low-molecular-weight heparins are the preferred agents for prophylaxis in pregnant women with inherited thrombophilia, with doses varying by thrombophilia type and associated risk factors.
Why the study?
Inherited thrombophilia combined with pregnancy increases thromboembolic risk and complications, but interpreting positive thrombophilia tests during pregnancy is difficult due to physiological coagulation changes.
Does thromboprophylaxis with low-molecular-weight heparins improve cardiovascular and pregnancy outcomes in pregnant women with inherited thrombophilia?
Does thromboprophylaxis with low-molecular-weight heparins improve cardiovascular and pregnancy outcomes in pregnant women with inherited thrombophilia?
This review highlights the importance of risk stratification and targeted thromboprophylaxis with low-molecular-weight heparins in pregnant women with inherited thrombophilia to prevent thromboembolic and pregnancy complications.
Authors
No takes yet. Share an insight, caveat, or question.
May inform prophylaxis decisions in thrombophilic pregnancies; leaves open need for RCTs to validate dosing by risk.
Trașcă et al. (2019) conducted a review in Inherited thrombophilia in pregnancy. Anticoagulant treatment (Low-molecular-weight heparins) was evaluated. Low-molecular-weight heparins are the preferred agents for prophylaxis in pregnant women with inherited thrombophilia, with doses varying by thrombophilia type and associated risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: